Similar Search Results

Economic valuation and determinants of informal care to people with Alzheimer’s disease

Peña-Longobardo, Luz María; Oliva, Juan - In: The European journal of health economics : HEPAC ; … 16 (2015) 5, pp. 507-515

Persistent link: https://www.econbiz.de/10011299216

Economic impact of patients admitted to stroke units in Spain

Alvarez-Sabín, Jose; Quintana, Manuel; Masjuan, Jaime; … - In: The European journal of health economics : HEPAC ; … 18 (2017) 4, pp. 449-458

Persistent link: https://www.econbiz.de/10011868663

The economic burden of disease of epithelial ovarian cancer in Spain : he OvarCost study

Delgado-Ortega, Laura; González-Domínguez, Almudena; … - In: The European journal of health economics : HEPAC ; … 20 (2019) 1, pp. 135-147

Persistent link: https://www.econbiz.de/10011998121

How relevant are social costs in economic evaluations? : the case of Alzheimer's disease

Peña-Longobardo, L. M.; Rodríguez-Sánchez, B.; … - In: The European journal of health economics : HEPAC ; … 20 (2019) 8, pp. 1207-1236

Persistent link: https://www.econbiz.de/10012221328

Does the inclusion of societal costs change the economic evaluations recommendations? : a systematic review for multiple sclerosis disease

Rodríguez-Sánchez, Beatriz; Daugbjerg, S.; … - In: The European journal of health economics 24 (2023) 2, pp. 247-277

Persistent link: https://www.econbiz.de/10014327973

Matters arising : cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis : a systematic review

Lazzaro, Carlo; Bergamaschi, Roberto; Zaffaroni, Mauro; … - 2025

Background In their interesting systematic review, Gallehzan et al. quoted our article Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis (RRMS) in Italy. While we are grateful to Gallehzan et al. for their interest in the...

Persistent link: https://www.econbiz.de/10015371820